ACT 35TH ANNUAL MEETING SURVEY

100% of survey complete.

Question Title

* 1. MEMBERSHIP STATUS

Member

Nonmember

If not, we'd be interested to know why.

Question Title

* 2. AFFILIATION

Industry

Academia

Government

Postdoc

Student

Other (please specify)

Question Title

* 3. HOW DID YOU HEAR ABOUT THE MEETING?

Previous ACT Meeting

Website

Colleague

ACT Marketing

Other (please specify)

Question Title

* 4. PLEASE EVALUATE THE OVERALL QUALITY OF THE SESSIONS

MONDAY PLENARY LECTURE—Deborah Blum

"The Poisoner's Guide to Life"

Excellent

Good

Average

Fair

Poor

Comments

Question Title

* 5. Symposium 1—From Mice to Men, Development of Human Drugs and Biologics under the Animal Rule

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Animal Model Qualification Process and the Medical Countermeasures Initiative—Owen McMaster	Animal Model Qualification Process and the Medical Countermeasures Initiative—Owen McMaster Excellent	Animal Model Qualification Process and the Medical Countermeasures Initiative—Owen McMaster Good	Animal Model Qualification Process and the Medical Countermeasures Initiative—Owen McMaster Average	Animal Model Qualification Process and the Medical Countermeasures Initiative—Owen McMaster Fair	Animal Model Qualification Process and the Medical Countermeasures Initiative—Owen McMaster Poor
Development of Brincidofovir for the Treatment of the Treatment of Smallpox under the Animal Rule—Lars C. Trost	Development of Brincidofovir for the Treatment of the Treatment of Smallpox under the Animal Rule—Lars C. Trost Excellent	Development of Brincidofovir for the Treatment of the Treatment of Smallpox under the Animal Rule—Lars C. Trost Good	Development of Brincidofovir for the Treatment of the Treatment of Smallpox under the Animal Rule—Lars C. Trost Average	Development of Brincidofovir for the Treatment of the Treatment of Smallpox under the Animal Rule—Lars C. Trost Fair	Development of Brincidofovir for the Treatment of the Treatment of Smallpox under the Animal Rule—Lars C. Trost Poor
Utilizing Well-Characterized Drug Development Tools for The Assessment of Medical Countermeasures: Anthrax Antitoxins—Gabe Meister	Utilizing Well-Characterized Drug Development Tools for The Assessment of Medical Countermeasures: Anthrax Antitoxins—Gabe Meister Excellent	Utilizing Well-Characterized Drug Development Tools for The Assessment of Medical Countermeasures: Anthrax Antitoxins—Gabe Meister Good	Utilizing Well-Characterized Drug Development Tools for The Assessment of Medical Countermeasures: Anthrax Antitoxins—Gabe Meister Average	Utilizing Well-Characterized Drug Development Tools for The Assessment of Medical Countermeasures: Anthrax Antitoxins—Gabe Meister Fair	Utilizing Well-Characterized Drug Development Tools for The Assessment of Medical Countermeasures: Anthrax Antitoxins—Gabe Meister Poor
Development of an Anthrax Vaccine under the Animal Rule: A Case Study—Barbara Mounho-Zamora	Development of an Anthrax Vaccine under the Animal Rule: A Case Study—Barbara Mounho-Zamora Excellent	Development of an Anthrax Vaccine under the Animal Rule: A Case Study—Barbara Mounho-Zamora Good	Development of an Anthrax Vaccine under the Animal Rule: A Case Study—Barbara Mounho-Zamora Average	Development of an Anthrax Vaccine under the Animal Rule: A Case Study—Barbara Mounho-Zamora Fair	Development of an Anthrax Vaccine under the Animal Rule: A Case Study—Barbara Mounho-Zamora Poor

Comments

Question Title

* 6. Symposium 2—What the AEL is the NOAEL?

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Recommended Practices for Defining and Communicating Adversity for Nonclinical Study Data—James A. Popp	Recommended Practices for Defining and Communicating Adversity for Nonclinical Study Data—James A. Popp Excellent	Recommended Practices for Defining and Communicating Adversity for Nonclinical Study Data—James A. Popp Good	Recommended Practices for Defining and Communicating Adversity for Nonclinical Study Data—James A. Popp Average	Recommended Practices for Defining and Communicating Adversity for Nonclinical Study Data—James A. Popp Fair	Recommended Practices for Defining and Communicating Adversity for Nonclinical Study Data—James A. Popp Poor
Determining Adverse Histopathology using a Weight of Evidence Approach—Daniel J. Patrick	Determining Adverse Histopathology using a Weight of Evidence Approach—Daniel J. Patrick Excellent	Determining Adverse Histopathology using a Weight of Evidence Approach—Daniel J. Patrick Good	Determining Adverse Histopathology using a Weight of Evidence Approach—Daniel J. Patrick Average	Determining Adverse Histopathology using a Weight of Evidence Approach—Daniel J. Patrick Fair	Determining Adverse Histopathology using a Weight of Evidence Approach—Daniel J. Patrick Poor
NOAEL Selection and Risk Assessment for Biologics and Other Nontraditional Small Molecules—Laine Peyton Myers	NOAEL Selection and Risk Assessment for Biologics and Other Nontraditional Small Molecules—Laine Peyton Myers Excellent	NOAEL Selection and Risk Assessment for Biologics and Other Nontraditional Small Molecules—Laine Peyton Myers Good	NOAEL Selection and Risk Assessment for Biologics and Other Nontraditional Small Molecules—Laine Peyton Myers Average	NOAEL Selection and Risk Assessment for Biologics and Other Nontraditional Small Molecules—Laine Peyton Myers Fair	NOAEL Selection and Risk Assessment for Biologics and Other Nontraditional Small Molecules—Laine Peyton Myers Poor
When Should Pharmacology/Superpharmacology Be Considered Adverse (Ever?)—Christopher Horvath	When Should Pharmacology/Superpharmacology Be Considered Adverse (Ever?)—Christopher Horvath Excellent	When Should Pharmacology/Superpharmacology Be Considered Adverse (Ever?)—Christopher Horvath Good	When Should Pharmacology/Superpharmacology Be Considered Adverse (Ever?)—Christopher Horvath Average	When Should Pharmacology/Superpharmacology Be Considered Adverse (Ever?)—Christopher Horvath Fair	When Should Pharmacology/Superpharmacology Be Considered Adverse (Ever?)—Christopher Horvath Poor

Comments

Question Title

* 7. Symposium 3—Systems Toxicology: The Future of Risk Assessment

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Translating Systems Toxicology-Based Assessment into Risk Management—Thomas Hartung	Translating Systems Toxicology-Based Assessment into Risk Management—Thomas Hartung Excellent	Translating Systems Toxicology-Based Assessment into Risk Management—Thomas Hartung Good	Translating Systems Toxicology-Based Assessment into Risk Management—Thomas Hartung Average	Translating Systems Toxicology-Based Assessment into Risk Management—Thomas Hartung Fair	Translating Systems Toxicology-Based Assessment into Risk Management—Thomas Hartung Poor
Experimental Enablers: The Pan-Omics View—Marcel Leist	Experimental Enablers: The Pan-Omics View—Marcel Leist Excellent	Experimental Enablers: The Pan-Omics View—Marcel Leist Good	Experimental Enablers: The Pan-Omics View—Marcel Leist Average	Experimental Enablers: The Pan-Omics View—Marcel Leist Fair	Experimental Enablers: The Pan-Omics View—Marcel Leist Poor
Computational Enablers: From Data Integration to Dynamic Modeling—Thomas B. Knudsen	Computational Enablers: From Data Integration to Dynamic Modeling—Thomas B. Knudsen Excellent	Computational Enablers: From Data Integration to Dynamic Modeling—Thomas B. Knudsen Good	Computational Enablers: From Data Integration to Dynamic Modeling—Thomas B. Knudsen Average	Computational Enablers: From Data Integration to Dynamic Modeling—Thomas B. Knudsen Fair	Computational Enablers: From Data Integration to Dynamic Modeling—Thomas B. Knudsen Poor
Implementing Systems Toxicology Approaches—Julia Hoeng	Implementing Systems Toxicology Approaches—Julia Hoeng Excellent	Implementing Systems Toxicology Approaches—Julia Hoeng Good	Implementing Systems Toxicology Approaches—Julia Hoeng Average	Implementing Systems Toxicology Approaches—Julia Hoeng Fair	Implementing Systems Toxicology Approaches—Julia Hoeng Poor

Comments

Question Title

* 8. Symposium 4—Anti-Drug Antibody-Independent Immune Responses to Biologics in Rodent Studies—Regulatory Success in Early Drug Development

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Clinical Impact of Rodent-Specific Immune-Related Reactions to Human Proteins—Joy Cavagnaro	Clinical Impact of Rodent-Specific Immune-Related Reactions to Human Proteins—Joy Cavagnaro Excellent	Clinical Impact of Rodent-Specific Immune-Related Reactions to Human Proteins—Joy Cavagnaro Good	Clinical Impact of Rodent-Specific Immune-Related Reactions to Human Proteins—Joy Cavagnaro Average	Clinical Impact of Rodent-Specific Immune-Related Reactions to Human Proteins—Joy Cavagnaro Fair	Clinical Impact of Rodent-Specific Immune-Related Reactions to Human Proteins—Joy Cavagnaro Poor
Non-ADA Mediated Anaphylactoid Reactions in Toxicology Studies with Rodents—Krishna Allamneni	Non-ADA Mediated Anaphylactoid Reactions in Toxicology Studies with Rodents—Krishna Allamneni Excellent	Non-ADA Mediated Anaphylactoid Reactions in Toxicology Studies with Rodents—Krishna Allamneni Good	Non-ADA Mediated Anaphylactoid Reactions in Toxicology Studies with Rodents—Krishna Allamneni Average	Non-ADA Mediated Anaphylactoid Reactions in Toxicology Studies with Rodents—Krishna Allamneni Fair	Non-ADA Mediated Anaphylactoid Reactions in Toxicology Studies with Rodents—Krishna Allamneni Poor
Immunotoxicoloogy Tools to Characterize Species-Specific Immune Reactions—Florence G. Burleson	Immunotoxicoloogy Tools to Characterize Species-Specific Immune Reactions—Florence G. Burleson Excellent	Immunotoxicoloogy Tools to Characterize Species-Specific Immune Reactions—Florence G. Burleson Good	Immunotoxicoloogy Tools to Characterize Species-Specific Immune Reactions—Florence G. Burleson Average	Immunotoxicoloogy Tools to Characterize Species-Specific Immune Reactions—Florence G. Burleson Fair	Immunotoxicoloogy Tools to Characterize Species-Specific Immune Reactions—Florence G. Burleson Poor
Regulatory Perspectives on the Rodent-Specific Immune Reactions—Jane Sohn	Regulatory Perspectives on the Rodent-Specific Immune Reactions—Jane Sohn Excellent	Regulatory Perspectives on the Rodent-Specific Immune Reactions—Jane Sohn Good	Regulatory Perspectives on the Rodent-Specific Immune Reactions—Jane Sohn Average	Regulatory Perspectives on the Rodent-Specific Immune Reactions—Jane Sohn Fair	Regulatory Perspectives on the Rodent-Specific Immune Reactions—Jane Sohn Poor

Comments

Question Title

* 9. Symposium 5—Use of Humanized Mouse Models in DMPK and Safety Testing of Compounds

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Nearly Human—The Potential of Chimeric Mice with Livers Colonized with Human Hepatocyte—Ian D. Wilson	Nearly Human—The Potential of Chimeric Mice with Livers Colonized with Human Hepatocyte—Ian D. Wilson Excellent	Nearly Human—The Potential of Chimeric Mice with Livers Colonized with Human Hepatocyte—Ian D. Wilson Good	Nearly Human—The Potential of Chimeric Mice with Livers Colonized with Human Hepatocyte—Ian D. Wilson Average	Nearly Human—The Potential of Chimeric Mice with Livers Colonized with Human Hepatocyte—Ian D. Wilson Fair	Nearly Human—The Potential of Chimeric Mice with Livers Colonized with Human Hepatocyte—Ian D. Wilson Poor
Application of Humanised Mouse Models to Study Anticancer Drug Efficacy and Toxicity—Charles Roland Wolf	Application of Humanised Mouse Models to Study Anticancer Drug Efficacy and Toxicity—Charles Roland Wolf Excellent	Application of Humanised Mouse Models to Study Anticancer Drug Efficacy and Toxicity—Charles Roland Wolf Good	Application of Humanised Mouse Models to Study Anticancer Drug Efficacy and Toxicity—Charles Roland Wolf Average	Application of Humanised Mouse Models to Study Anticancer Drug Efficacy and Toxicity—Charles Roland Wolf Fair	Application of Humanised Mouse Models to Study Anticancer Drug Efficacy and Toxicity—Charles Roland Wolf Poor
Utility of Humanized Mice in the Assessment of Biological Drug Products—Kristina Howard	Utility of Humanized Mice in the Assessment of Biological Drug Products—Kristina Howard Excellent	Utility of Humanized Mice in the Assessment of Biological Drug Products—Kristina Howard Good	Utility of Humanized Mice in the Assessment of Biological Drug Products—Kristina Howard Average	Utility of Humanized Mice in the Assessment of Biological Drug Products—Kristina Howard Fair	Utility of Humanized Mice in the Assessment of Biological Drug Products—Kristina Howard Poor
Humanized Mouse Models—Applications in Preclinical Testing—Alema Galijatovic-Idrizbegovic	Humanized Mouse Models—Applications in Preclinical Testing—Alema Galijatovic-Idrizbegovic Excellent	Humanized Mouse Models—Applications in Preclinical Testing—Alema Galijatovic-Idrizbegovic Good	Humanized Mouse Models—Applications in Preclinical Testing—Alema Galijatovic-Idrizbegovic Average	Humanized Mouse Models—Applications in Preclinical Testing—Alema Galijatovic-Idrizbegovic Fair	Humanized Mouse Models—Applications in Preclinical Testing—Alema Galijatovic-Idrizbegovic Poor
Regulatory Perspective on Alternative Animal Models—Mark W. Powley	Regulatory Perspective on Alternative Animal Models—Mark W. Powley Excellent	Regulatory Perspective on Alternative Animal Models—Mark W. Powley Good	Regulatory Perspective on Alternative Animal Models—Mark W. Powley Average	Regulatory Perspective on Alternative Animal Models—Mark W. Powley Fair	Regulatory Perspective on Alternative Animal Models—Mark W. Powley Poor

Comments

Question Title

* 10. Symposium 6—Targeted Cancer Therapeutics: Concepts and Strategies to Improve Oncology Drug Development

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Introduction: Targeted Cancer Therapies: Concepts and Strategies to Improve Oncology Drug Development—Elaine Knight	Introduction: Targeted Cancer Therapies: Concepts and Strategies to Improve Oncology Drug Development—Elaine Knight Excellent	Introduction: Targeted Cancer Therapies: Concepts and Strategies to Improve Oncology Drug Development—Elaine Knight Good	Introduction: Targeted Cancer Therapies: Concepts and Strategies to Improve Oncology Drug Development—Elaine Knight Average	Introduction: Targeted Cancer Therapies: Concepts and Strategies to Improve Oncology Drug Development—Elaine Knight Fair	Introduction: Targeted Cancer Therapies: Concepts and Strategies to Improve Oncology Drug Development—Elaine Knight Poor
Cancer Biology and the Discovery of Targeted Therapies—Alan C. Rigby	Cancer Biology and the Discovery of Targeted Therapies—Alan C. Rigby Excellent	Cancer Biology and the Discovery of Targeted Therapies—Alan C. Rigby Good	Cancer Biology and the Discovery of Targeted Therapies—Alan C. Rigby Average	Cancer Biology and the Discovery of Targeted Therapies—Alan C. Rigby Fair	Cancer Biology and the Discovery of Targeted Therapies—Alan C. Rigby Poor
Targeted Anticancer Pharmaceuticals: Off-Target and On-Target Toxicities—Vijayapal Reddy	Targeted Anticancer Pharmaceuticals: Off-Target and On-Target Toxicities—Vijayapal Reddy Excellent	Targeted Anticancer Pharmaceuticals: Off-Target and On-Target Toxicities—Vijayapal Reddy Good	Targeted Anticancer Pharmaceuticals: Off-Target and On-Target Toxicities—Vijayapal Reddy Average	Targeted Anticancer Pharmaceuticals: Off-Target and On-Target Toxicities—Vijayapal Reddy Fair	Targeted Anticancer Pharmaceuticals: Off-Target and On-Target Toxicities—Vijayapal Reddy Poor
Transforming the NCI Experimental Therapeutic Program as It Relates to Clinical Evaluation of Targeted Therapies—S. Percy Ivy	Transforming the NCI Experimental Therapeutic Program as It Relates to Clinical Evaluation of Targeted Therapies—S. Percy Ivy Excellent	Transforming the NCI Experimental Therapeutic Program as It Relates to Clinical Evaluation of Targeted Therapies—S. Percy Ivy Good	Transforming the NCI Experimental Therapeutic Program as It Relates to Clinical Evaluation of Targeted Therapies—S. Percy Ivy Average	Transforming the NCI Experimental Therapeutic Program as It Relates to Clinical Evaluation of Targeted Therapies—S. Percy Ivy Fair	Transforming the NCI Experimental Therapeutic Program as It Relates to Clinical Evaluation of Targeted Therapies—S. Percy Ivy Poor
Regulatory Perspective on the Development of Targeted Anticancer Therapeutics—Todd R. Palmby	Regulatory Perspective on the Development of Targeted Anticancer Therapeutics—Todd R. Palmby Excellent	Regulatory Perspective on the Development of Targeted Anticancer Therapeutics—Todd R. Palmby Good	Regulatory Perspective on the Development of Targeted Anticancer Therapeutics—Todd R. Palmby Average	Regulatory Perspective on the Development of Targeted Anticancer Therapeutics—Todd R. Palmby Fair	Regulatory Perspective on the Development of Targeted Anticancer Therapeutics—Todd R. Palmby Poor

Comments

Question Title

* 11. Symposium 7—Breathe In, Breathe Out, It's Easy: What You Need to Know about Developing Inhaled Drugs

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Overview: It Sucks and Blows, Lung Function—Jeff Tepper	Overview: It Sucks and Blows, Lung Function—Jeff Tepper Excellent	Overview: It Sucks and Blows, Lung Function—Jeff Tepper Good	Overview: It Sucks and Blows, Lung Function—Jeff Tepper Average	Overview: It Sucks and Blows, Lung Function—Jeff Tepper Fair	Overview: It Sucks and Blows, Lung Function—Jeff Tepper Poor
Dose is Dose, Right? Determining Pulmonary Dose in Clinical and Nonclinical Studies—Philip Kuehl	Dose is Dose, Right? Determining Pulmonary Dose in Clinical and Nonclinical Studies—Philip Kuehl Excellent	Dose is Dose, Right? Determining Pulmonary Dose in Clinical and Nonclinical Studies—Philip Kuehl Good	Dose is Dose, Right? Determining Pulmonary Dose in Clinical and Nonclinical Studies—Philip Kuehl Average	Dose is Dose, Right? Determining Pulmonary Dose in Clinical and Nonclinical Studies—Philip Kuehl Fair	Dose is Dose, Right? Determining Pulmonary Dose in Clinical and Nonclinical Studies—Philip Kuehl Poor
You Need How Much!!! Test Article Conservation During In Vivo Inhalation Studies—Stuart Cracknell	You Need How Much!!! Test Article Conservation During In Vivo Inhalation Studies—Stuart Cracknell Excellent	You Need How Much!!! Test Article Conservation During In Vivo Inhalation Studies—Stuart Cracknell Good	You Need How Much!!! Test Article Conservation During In Vivo Inhalation Studies—Stuart Cracknell Average	You Need How Much!!! Test Article Conservation During In Vivo Inhalation Studies—Stuart Cracknell Fair	You Need How Much!!! Test Article Conservation During In Vivo Inhalation Studies—Stuart Cracknell Poor
Tour of the Respiratory Tract with Stops at Sites of Toxicological Significance—Kristen Nikula	Tour of the Respiratory Tract with Stops at Sites of Toxicological Significance—Kristen Nikula Excellent	Tour of the Respiratory Tract with Stops at Sites of Toxicological Significance—Kristen Nikula Good	Tour of the Respiratory Tract with Stops at Sites of Toxicological Significance—Kristen Nikula Average	Tour of the Respiratory Tract with Stops at Sites of Toxicological Significance—Kristen Nikula Fair	Tour of the Respiratory Tract with Stops at Sites of Toxicological Significance—Kristen Nikula Poor
Regulatory Considerations in Nonclinical Safety Evaluations of Inhalation Drugs—Luqi Pei	Regulatory Considerations in Nonclinical Safety Evaluations of Inhalation Drugs—Luqi Pei Excellent	Regulatory Considerations in Nonclinical Safety Evaluations of Inhalation Drugs—Luqi Pei Good	Regulatory Considerations in Nonclinical Safety Evaluations of Inhalation Drugs—Luqi Pei Average	Regulatory Considerations in Nonclinical Safety Evaluations of Inhalation Drugs—Luqi Pei Fair	Regulatory Considerations in Nonclinical Safety Evaluations of Inhalation Drugs—Luqi Pei Poor

Comments

Question Title

* 12. Symposium 8—Cardiovascular Safety Evaluation—In Vitro to Humans

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Cardiovascular Safety Assessments During Drug Development: Current Approach and the Need for a New Paradigm—Philip Sager	Cardiovascular Safety Assessments During Drug Development: Current Approach and the Need for a New Paradigm—Philip Sager Excellent	Cardiovascular Safety Assessments During Drug Development: Current Approach and the Need for a New Paradigm—Philip Sager Good	Cardiovascular Safety Assessments During Drug Development: Current Approach and the Need for a New Paradigm—Philip Sager Average	Cardiovascular Safety Assessments During Drug Development: Current Approach and the Need for a New Paradigm—Philip Sager Fair	Cardiovascular Safety Assessments During Drug Development: Current Approach and the Need for a New Paradigm—Philip Sager Poor
In Vitro Cardiovascular Safety—Discovery Screen to GLP Studies—Bernard Fermini	In Vitro Cardiovascular Safety—Discovery Screen to GLP Studies—Bernard Fermini Excellent	In Vitro Cardiovascular Safety—Discovery Screen to GLP Studies—Bernard Fermini Good	In Vitro Cardiovascular Safety—Discovery Screen to GLP Studies—Bernard Fermini Average	In Vitro Cardiovascular Safety—Discovery Screen to GLP Studies—Bernard Fermini Fair	In Vitro Cardiovascular Safety—Discovery Screen to GLP Studies—Bernard Fermini Poor
Integrated Systems for Evaluation of Cardiovascular Electrophysiology Safety: Secondary In Vitro Assays and In Vivo Evaluations—Gary Gintant	Integrated Systems for Evaluation of Cardiovascular Electrophysiology Safety: Secondary In Vitro Assays and In Vivo Evaluations—Gary Gintant Excellent	Integrated Systems for Evaluation of Cardiovascular Electrophysiology Safety: Secondary In Vitro Assays and In Vivo Evaluations—Gary Gintant Good	Integrated Systems for Evaluation of Cardiovascular Electrophysiology Safety: Secondary In Vitro Assays and In Vivo Evaluations—Gary Gintant Average	Integrated Systems for Evaluation of Cardiovascular Electrophysiology Safety: Secondary In Vitro Assays and In Vivo Evaluations—Gary Gintant Fair	Integrated Systems for Evaluation of Cardiovascular Electrophysiology Safety: Secondary In Vitro Assays and In Vivo Evaluations—Gary Gintant Poor
Regulatory Thinking of the Current Guidelines on Cardiovascular Evaluation—Beyond QTc—Norman Stockbridge	Regulatory Thinking of the Current Guidelines on Cardiovascular Evaluation—Beyond QTc—Norman Stockbridge Excellent	Regulatory Thinking of the Current Guidelines on Cardiovascular Evaluation—Beyond QTc—Norman Stockbridge Good	Regulatory Thinking of the Current Guidelines on Cardiovascular Evaluation—Beyond QTc—Norman Stockbridge Average	Regulatory Thinking of the Current Guidelines on Cardiovascular Evaluation—Beyond QTc—Norman Stockbridge Fair	Regulatory Thinking of the Current Guidelines on Cardiovascular Evaluation—Beyond QTc—Norman Stockbridge Poor
Experiences with Elements of Comprehensive In Vitro Proarrhythmia Assay (CiPA)—Arthur “Buzz” Brown	Experiences with Elements of Comprehensive In Vitro Proarrhythmia Assay (CiPA)—Arthur “Buzz” Brown Excellent	Experiences with Elements of Comprehensive In Vitro Proarrhythmia Assay (CiPA)—Arthur “Buzz” Brown Good	Experiences with Elements of Comprehensive In Vitro Proarrhythmia Assay (CiPA)—Arthur “Buzz” Brown Average	Experiences with Elements of Comprehensive In Vitro Proarrhythmia Assay (CiPA)—Arthur “Buzz” Brown Fair	Experiences with Elements of Comprehensive In Vitro Proarrhythmia Assay (CiPA)—Arthur “Buzz” Brown Poor

Comments

Question Title

* 13. Symposium 9—Centrally Administered Compounds in Small and Large Species—Dose Routes, Study Considerations, and Data Interpretation

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Development of CNS Administered Biologics: Overview, Challenges, and a Case History—Brian R. Vuillemenot	Development of CNS Administered Biologics: Overview, Challenges, and a Case History—Brian R. Vuillemenot Excellent	Development of CNS Administered Biologics: Overview, Challenges, and a Case History—Brian R. Vuillemenot Good	Development of CNS Administered Biologics: Overview, Challenges, and a Case History—Brian R. Vuillemenot Average	Development of CNS Administered Biologics: Overview, Challenges, and a Case History—Brian R. Vuillemenot Fair	Development of CNS Administered Biologics: Overview, Challenges, and a Case History—Brian R. Vuillemenot Poor
Methodology of Central Drug Delivery and Cerebrospinal Fluid Collection in the Sheep, Dog and Rat Model—Eric Adams	Methodology of Central Drug Delivery and Cerebrospinal Fluid Collection in the Sheep, Dog and Rat Model—Eric Adams Excellent	Methodology of Central Drug Delivery and Cerebrospinal Fluid Collection in the Sheep, Dog and Rat Model—Eric Adams Good	Methodology of Central Drug Delivery and Cerebrospinal Fluid Collection in the Sheep, Dog and Rat Model—Eric Adams Average	Methodology of Central Drug Delivery and Cerebrospinal Fluid Collection in the Sheep, Dog and Rat Model—Eric Adams Fair	Methodology of Central Drug Delivery and Cerebrospinal Fluid Collection in the Sheep, Dog and Rat Model—Eric Adams Poor
Procedures for Intrathecal Drug Delivery and CSF Sampling in Nonhuman Primates Studies—Sven Korte	Procedures for Intrathecal Drug Delivery and CSF Sampling in Nonhuman Primates Studies—Sven Korte Excellent	Procedures for Intrathecal Drug Delivery and CSF Sampling in Nonhuman Primates Studies—Sven Korte Good	Procedures for Intrathecal Drug Delivery and CSF Sampling in Nonhuman Primates Studies—Sven Korte Average	Procedures for Intrathecal Drug Delivery and CSF Sampling in Nonhuman Primates Studies—Sven Korte Fair	Procedures for Intrathecal Drug Delivery and CSF Sampling in Nonhuman Primates Studies—Sven Korte Poor
Morphologic Assessment of Studies Involving Direct Delivery to the Central Nervous System—Mark T. Butt	Morphologic Assessment of Studies Involving Direct Delivery to the Central Nervous System—Mark T. Butt Excellent	Morphologic Assessment of Studies Involving Direct Delivery to the Central Nervous System—Mark T. Butt Good	Morphologic Assessment of Studies Involving Direct Delivery to the Central Nervous System—Mark T. Butt Average	Morphologic Assessment of Studies Involving Direct Delivery to the Central Nervous System—Mark T. Butt Fair	Morphologic Assessment of Studies Involving Direct Delivery to the Central Nervous System—Mark T. Butt Poor

Comments

Question Title

* 14. Symposium 10—Cytokines: The Good, the Bad, and the Deadly

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Cytokine Explosion: Rocking the World of Toxicology—Thulasi Ramani	Cytokine Explosion: Rocking the World of Toxicology—Thulasi Ramani Excellent	Cytokine Explosion: Rocking the World of Toxicology—Thulasi Ramani Good	Cytokine Explosion: Rocking the World of Toxicology—Thulasi Ramani Average	Cytokine Explosion: Rocking the World of Toxicology—Thulasi Ramani Fair	Cytokine Explosion: Rocking the World of Toxicology—Thulasi Ramani Poor
Therapeutic Cytokine-Blocking Antibodies—Daniel Weinstock	Therapeutic Cytokine-Blocking Antibodies—Daniel Weinstock Excellent	Therapeutic Cytokine-Blocking Antibodies—Daniel Weinstock Good	Therapeutic Cytokine-Blocking Antibodies—Daniel Weinstock Average	Therapeutic Cytokine-Blocking Antibodies—Daniel Weinstock Fair	Therapeutic Cytokine-Blocking Antibodies—Daniel Weinstock Poor
Safety Evaluation of Cytokine Therapeutics: Translation of Preclinical Data to the Clinic—Barbara Mounho-Zamora	Safety Evaluation of Cytokine Therapeutics: Translation of Preclinical Data to the Clinic—Barbara Mounho-Zamora Excellent	Safety Evaluation of Cytokine Therapeutics: Translation of Preclinical Data to the Clinic—Barbara Mounho-Zamora Good	Safety Evaluation of Cytokine Therapeutics: Translation of Preclinical Data to the Clinic—Barbara Mounho-Zamora Average	Safety Evaluation of Cytokine Therapeutics: Translation of Preclinical Data to the Clinic—Barbara Mounho-Zamora Fair	Safety Evaluation of Cytokine Therapeutics: Translation of Preclinical Data to the Clinic—Barbara Mounho-Zamora Poor
Targeting Cytokine Pathways to Treat Disease—Patricia Ryan	Targeting Cytokine Pathways to Treat Disease—Patricia Ryan Excellent	Targeting Cytokine Pathways to Treat Disease—Patricia Ryan Good	Targeting Cytokine Pathways to Treat Disease—Patricia Ryan Average	Targeting Cytokine Pathways to Treat Disease—Patricia Ryan Fair	Targeting Cytokine Pathways to Treat Disease—Patricia Ryan Poor
Beyond TeGenero—Development of Targeted Therapeutics without Deadly Consequences—Theodora Salcedo	Beyond TeGenero—Development of Targeted Therapeutics without Deadly Consequences—Theodora Salcedo Excellent	Beyond TeGenero—Development of Targeted Therapeutics without Deadly Consequences—Theodora Salcedo Good	Beyond TeGenero—Development of Targeted Therapeutics without Deadly Consequences—Theodora Salcedo Average	Beyond TeGenero—Development of Targeted Therapeutics without Deadly Consequences—Theodora Salcedo Fair	Beyond TeGenero—Development of Targeted Therapeutics without Deadly Consequences—Theodora Salcedo Poor
Cytokines as Biomarkers for Immunotoxicity—Gregory Bannish	Cytokines as Biomarkers for Immunotoxicity—Gregory Bannish Excellent	Cytokines as Biomarkers for Immunotoxicity—Gregory Bannish Good	Cytokines as Biomarkers for Immunotoxicity—Gregory Bannish Average	Cytokines as Biomarkers for Immunotoxicity—Gregory Bannish Fair	Cytokines as Biomarkers for Immunotoxicity—Gregory Bannish Poor

Comments

Question Title

* 15. Symposium 11—Differentiating Adverse from Adaptive Changes in Toxicology

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
A Whole-Animal Overview of Adaptive versus Adverse Change—Peter C. Mann	A Whole-Animal Overview of Adaptive versus Adverse Change—Peter C. Mann Excellent	A Whole-Animal Overview of Adaptive versus Adverse Change—Peter C. Mann Good	A Whole-Animal Overview of Adaptive versus Adverse Change—Peter C. Mann Average	A Whole-Animal Overview of Adaptive versus Adverse Change—Peter C. Mann Fair	A Whole-Animal Overview of Adaptive versus Adverse Change—Peter C. Mann Poor
Identifying Adverse Organ Responses: The Liver as Paradigm—Robert R. Maronpot	Identifying Adverse Organ Responses: The Liver as Paradigm—Robert R. Maronpot Excellent	Identifying Adverse Organ Responses: The Liver as Paradigm—Robert R. Maronpot Good	Identifying Adverse Organ Responses: The Liver as Paradigm—Robert R. Maronpot Average	Identifying Adverse Organ Responses: The Liver as Paradigm—Robert R. Maronpot Fair	Identifying Adverse Organ Responses: The Liver as Paradigm—Robert R. Maronpot Poor
Using Toxicogenomics in Assessing Adaptive versus Adverse Effects—Russell Thomas	Using Toxicogenomics in Assessing Adaptive versus Adverse Effects—Russell Thomas Excellent	Using Toxicogenomics in Assessing Adaptive versus Adverse Effects—Russell Thomas Good	Using Toxicogenomics in Assessing Adaptive versus Adverse Effects—Russell Thomas Average	Using Toxicogenomics in Assessing Adaptive versus Adverse Effects—Russell Thomas Fair	Using Toxicogenomics in Assessing Adaptive versus Adverse Effects—Russell Thomas Poor
Differentiating Adaptive and Adverse Changes: A Regulatory Perspective—Timothy J. McGovern	Differentiating Adaptive and Adverse Changes: A Regulatory Perspective—Timothy J. McGovern Excellent	Differentiating Adaptive and Adverse Changes: A Regulatory Perspective—Timothy J. McGovern Good	Differentiating Adaptive and Adverse Changes: A Regulatory Perspective—Timothy J. McGovern Average	Differentiating Adaptive and Adverse Changes: A Regulatory Perspective—Timothy J. McGovern Fair	Differentiating Adaptive and Adverse Changes: A Regulatory Perspective—Timothy J. McGovern Poor

Comments

Question Title

* 16. Symposium 12—In Silico Methods for Mutagenicity Prediction vis a vis ICH M7 Guidance

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Risk Characterization of Mutagenic Impurities—Joel Bercu	Risk Characterization of Mutagenic Impurities—Joel Bercu Excellent	Risk Characterization of Mutagenic Impurities—Joel Bercu Good	Risk Characterization of Mutagenic Impurities—Joel Bercu Average	Risk Characterization of Mutagenic Impurities—Joel Bercu Fair	Risk Characterization of Mutagenic Impurities—Joel Bercu Poor
Regulatory Implementation of ICH M7—Mark W. Powley	Regulatory Implementation of ICH M7—Mark W. Powley Excellent	Regulatory Implementation of ICH M7—Mark W. Powley Good	Regulatory Implementation of ICH M7—Mark W. Powley Average	Regulatory Implementation of ICH M7—Mark W. Powley Fair	Regulatory Implementation of ICH M7—Mark W. Powley Poor
Living with ICH M7: The Practical Application of Two In Silico Systems in Screening for GTIs—Nigel Greene	Living with ICH M7: The Practical Application of Two In Silico Systems in Screening for GTIs—Nigel Greene Excellent	Living with ICH M7: The Practical Application of Two In Silico Systems in Screening for GTIs—Nigel Greene Good	Living with ICH M7: The Practical Application of Two In Silico Systems in Screening for GTIs—Nigel Greene Average	Living with ICH M7: The Practical Application of Two In Silico Systems in Screening for GTIs—Nigel Greene Fair	Living with ICH M7: The Practical Application of Two In Silico Systems in Screening for GTIs—Nigel Greene Poor
ICH M7: Risk Assessment with In-House and Off-the-Shelf In Silico Mutagenicity Predictors—Robert A. Jolly	ICH M7: Risk Assessment with In-House and Off-the-Shelf In Silico Mutagenicity Predictors—Robert A. Jolly Excellent	ICH M7: Risk Assessment with In-House and Off-the-Shelf In Silico Mutagenicity Predictors—Robert A. Jolly Good	ICH M7: Risk Assessment with In-House and Off-the-Shelf In Silico Mutagenicity Predictors—Robert A. Jolly Average	ICH M7: Risk Assessment with In-House and Off-the-Shelf In Silico Mutagenicity Predictors—Robert A. Jolly Fair	ICH M7: Risk Assessment with In-House and Off-the-Shelf In Silico Mutagenicity Predictors—Robert A. Jolly Poor
Using In Silico Tools for the Assessment of Genotoxic Impurities—Chris Barber	Using In Silico Tools for the Assessment of Genotoxic Impurities—Chris Barber Excellent	Using In Silico Tools for the Assessment of Genotoxic Impurities—Chris Barber Good	Using In Silico Tools for the Assessment of Genotoxic Impurities—Chris Barber Average	Using In Silico Tools for the Assessment of Genotoxic Impurities—Chris Barber Fair	Using In Silico Tools for the Assessment of Genotoxic Impurities—Chris Barber Poor
Physico-Chemical Modulation of DEREK Structural Alerts—Vijay K. Gombar	Physico-Chemical Modulation of DEREK Structural Alerts—Vijay K. Gombar Excellent	Physico-Chemical Modulation of DEREK Structural Alerts—Vijay K. Gombar Good	Physico-Chemical Modulation of DEREK Structural Alerts—Vijay K. Gombar Average	Physico-Chemical Modulation of DEREK Structural Alerts—Vijay K. Gombar Fair	Physico-Chemical Modulation of DEREK Structural Alerts—Vijay K. Gombar Poor

Comments

Question Title

* 17. WEDNESDAY PLENARY LECTURE—Alison Van Eenennaam, PhD

"Food and Feed Safety of Genetically Modified Organisms: The Hype and the Facts"

Excellent

Good

Average

Fair

Poor

Comments

Question Title

* 18. Symposium 13—Novel Therapeutics in Oncology: Recent Advances and Considerations for Nonclinical Safety Evaluation

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Antibody Drug Conjugates: Recent Developments and Future Perspectives—Laurie Tatalick	Antibody Drug Conjugates: Recent Developments and Future Perspectives—Laurie Tatalick Excellent	Antibody Drug Conjugates: Recent Developments and Future Perspectives—Laurie Tatalick Good	Antibody Drug Conjugates: Recent Developments and Future Perspectives—Laurie Tatalick Average	Antibody Drug Conjugates: Recent Developments and Future Perspectives—Laurie Tatalick Fair	Antibody Drug Conjugates: Recent Developments and Future Perspectives—Laurie Tatalick Poor
Advances in Bispecific Antibodies Facilitating Novel Therapeutic Opportunities—Paul Moore	Advances in Bispecific Antibodies Facilitating Novel Therapeutic Opportunities—Paul Moore Excellent	Advances in Bispecific Antibodies Facilitating Novel Therapeutic Opportunities—Paul Moore Good	Advances in Bispecific Antibodies Facilitating Novel Therapeutic Opportunities—Paul Moore Average	Advances in Bispecific Antibodies Facilitating Novel Therapeutic Opportunities—Paul Moore Fair	Advances in Bispecific Antibodies Facilitating Novel Therapeutic Opportunities—Paul Moore Poor
Nonclinical Safety Evaluation of Novel Ab-based Therapeutics for Oncology—Magali Guffroy	Nonclinical Safety Evaluation of Novel Ab-based Therapeutics for Oncology—Magali Guffroy Excellent	Nonclinical Safety Evaluation of Novel Ab-based Therapeutics for Oncology—Magali Guffroy Good	Nonclinical Safety Evaluation of Novel Ab-based Therapeutics for Oncology—Magali Guffroy Average	Nonclinical Safety Evaluation of Novel Ab-based Therapeutics for Oncology—Magali Guffroy Fair	Nonclinical Safety Evaluation of Novel Ab-based Therapeutics for Oncology—Magali Guffroy Poor
Using the Power of the Immune System to Target Cancer—David W. Clarke	Using the Power of the Immune System to Target Cancer—David W. Clarke Excellent	Using the Power of the Immune System to Target Cancer—David W. Clarke Good	Using the Power of the Immune System to Target Cancer—David W. Clarke Average	Using the Power of the Immune System to Target Cancer—David W. Clarke Fair	Using the Power of the Immune System to Target Cancer—David W. Clarke Poor

Comments

Question Title

* 19. Symposium 14—Applied Nanotoxicology

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Introduction to Applied Nanomaterial Toxicology and Applied Nanotoxicology for Pharmaceuticals and Medical Devices—Dave Hobson	Introduction to Applied Nanomaterial Toxicology and Applied Nanotoxicology for Pharmaceuticals and Medical Devices—Dave Hobson Excellent	Introduction to Applied Nanomaterial Toxicology and Applied Nanotoxicology for Pharmaceuticals and Medical Devices—Dave Hobson Good	Introduction to Applied Nanomaterial Toxicology and Applied Nanotoxicology for Pharmaceuticals and Medical Devices—Dave Hobson Average	Introduction to Applied Nanomaterial Toxicology and Applied Nanotoxicology for Pharmaceuticals and Medical Devices—Dave Hobson Fair	Introduction to Applied Nanomaterial Toxicology and Applied Nanotoxicology for Pharmaceuticals and Medical Devices—Dave Hobson Poor
Assessing the Biological Fate of Ingested Nanomaterials—Steve Roberts	Assessing the Biological Fate of Ingested Nanomaterials—Steve Roberts Excellent	Assessing the Biological Fate of Ingested Nanomaterials—Steve Roberts Good	Assessing the Biological Fate of Ingested Nanomaterials—Steve Roberts Average	Assessing the Biological Fate of Ingested Nanomaterials—Steve Roberts Fair	Assessing the Biological Fate of Ingested Nanomaterials—Steve Roberts Poor
Nanoparticles as an Emerging Environmental and Occupational Hazard—Toxicology Prospective—Anna Shvedova	Nanoparticles as an Emerging Environmental and Occupational Hazard—Toxicology Prospective—Anna Shvedova Excellent	Nanoparticles as an Emerging Environmental and Occupational Hazard—Toxicology Prospective—Anna Shvedova Good	Nanoparticles as an Emerging Environmental and Occupational Hazard—Toxicology Prospective—Anna Shvedova Average	Nanoparticles as an Emerging Environmental and Occupational Hazard—Toxicology Prospective—Anna Shvedova Fair	Nanoparticles as an Emerging Environmental and Occupational Hazard—Toxicology Prospective—Anna Shvedova Poor
Consumer Product Example: Strategies for Setting Occupational Exposure Limits for Engineered Titanium Dioxide Nanomaterials—David Warheit	Consumer Product Example: Strategies for Setting Occupational Exposure Limits for Engineered Titanium Dioxide Nanomaterials—David Warheit Excellent	Consumer Product Example: Strategies for Setting Occupational Exposure Limits for Engineered Titanium Dioxide Nanomaterials—David Warheit Good	Consumer Product Example: Strategies for Setting Occupational Exposure Limits for Engineered Titanium Dioxide Nanomaterials—David Warheit Average	Consumer Product Example: Strategies for Setting Occupational Exposure Limits for Engineered Titanium Dioxide Nanomaterials—David Warheit Fair	Consumer Product Example: Strategies for Setting Occupational Exposure Limits for Engineered Titanium Dioxide Nanomaterials—David Warheit Poor
Applied Considerations for Safety Assessment of Food Products and Food Packaging Containing Nanomaterials—Robin Guy	Applied Considerations for Safety Assessment of Food Products and Food Packaging Containing Nanomaterials—Robin Guy Excellent	Applied Considerations for Safety Assessment of Food Products and Food Packaging Containing Nanomaterials—Robin Guy Good	Applied Considerations for Safety Assessment of Food Products and Food Packaging Containing Nanomaterials—Robin Guy Average	Applied Considerations for Safety Assessment of Food Products and Food Packaging Containing Nanomaterials—Robin Guy Fair	Applied Considerations for Safety Assessment of Food Products and Food Packaging Containing Nanomaterials—Robin Guy Poor

Comments

Question Title

* 20. Symposium 15—Stem Cells Research

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Where Is the Field of Regenerative Medicine Going?—Alan Trounson	Where Is the Field of Regenerative Medicine Going?—Alan Trounson Excellent	Where Is the Field of Regenerative Medicine Going?—Alan Trounson Good	Where Is the Field of Regenerative Medicine Going?—Alan Trounson Average	Where Is the Field of Regenerative Medicine Going?—Alan Trounson Fair	Where Is the Field of Regenerative Medicine Going?—Alan Trounson Poor
Applications of Stem Cell Technologies in Drug Discovery—Kyle Kolaja	Applications of Stem Cell Technologies in Drug Discovery—Kyle Kolaja Excellent	Applications of Stem Cell Technologies in Drug Discovery—Kyle Kolaja Good	Applications of Stem Cell Technologies in Drug Discovery—Kyle Kolaja Average	Applications of Stem Cell Technologies in Drug Discovery—Kyle Kolaja Fair	Applications of Stem Cell Technologies in Drug Discovery—Kyle Kolaja Poor
Pathology Techniques to Aid the Development and Understanding Advanced Therapy Medicinal Products (ATMPs)—Klaus Weber	Pathology Techniques to Aid the Development and Understanding Advanced Therapy Medicinal Products (ATMPs)—Klaus Weber Excellent	Pathology Techniques to Aid the Development and Understanding Advanced Therapy Medicinal Products (ATMPs)—Klaus Weber Good	Pathology Techniques to Aid the Development and Understanding Advanced Therapy Medicinal Products (ATMPs)—Klaus Weber Average	Pathology Techniques to Aid the Development and Understanding Advanced Therapy Medicinal Products (ATMPs)—Klaus Weber Fair	Pathology Techniques to Aid the Development and Understanding Advanced Therapy Medicinal Products (ATMPs)—Klaus Weber Poor
Advancing Engineered Lung Tissues to the Clinic: Considerations for Animal Models and Toxicology Studies—Thomas Petersen	Advancing Engineered Lung Tissues to the Clinic: Considerations for Animal Models and Toxicology Studies—Thomas Petersen Excellent	Advancing Engineered Lung Tissues to the Clinic: Considerations for Animal Models and Toxicology Studies—Thomas Petersen Good	Advancing Engineered Lung Tissues to the Clinic: Considerations for Animal Models and Toxicology Studies—Thomas Petersen Average	Advancing Engineered Lung Tissues to the Clinic: Considerations for Animal Models and Toxicology Studies—Thomas Petersen Fair	Advancing Engineered Lung Tissues to the Clinic: Considerations for Animal Models and Toxicology Studies—Thomas Petersen Poor

Comments

Question Title

* 21. Symposium 16—Safety Assessment Updates for Preventive Vaccines and Vaccine Adjuvants

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Rationale for Use of Adjuvants in Vaccines and Overview of Adjuvant Classes and Pathways—Jayanthi Wolf	Rationale for Use of Adjuvants in Vaccines and Overview of Adjuvant Classes and Pathways—Jayanthi Wolf Excellent	Rationale for Use of Adjuvants in Vaccines and Overview of Adjuvant Classes and Pathways—Jayanthi Wolf Good	Rationale for Use of Adjuvants in Vaccines and Overview of Adjuvant Classes and Pathways—Jayanthi Wolf Average	Rationale for Use of Adjuvants in Vaccines and Overview of Adjuvant Classes and Pathways—Jayanthi Wolf Fair	Rationale for Use of Adjuvants in Vaccines and Overview of Adjuvant Classes and Pathways—Jayanthi Wolf Poor
Regulatory Update including New WHO Guidelines for Adjuvanted Vaccines and Clinical Considerations—Carmen Collazo-Custodio	Regulatory Update including New WHO Guidelines for Adjuvanted Vaccines and Clinical Considerations—Carmen Collazo-Custodio Excellent	Regulatory Update including New WHO Guidelines for Adjuvanted Vaccines and Clinical Considerations—Carmen Collazo-Custodio Good	Regulatory Update including New WHO Guidelines for Adjuvanted Vaccines and Clinical Considerations—Carmen Collazo-Custodio Average	Regulatory Update including New WHO Guidelines for Adjuvanted Vaccines and Clinical Considerations—Carmen Collazo-Custodio Fair	Regulatory Update including New WHO Guidelines for Adjuvanted Vaccines and Clinical Considerations—Carmen Collazo-Custodio Poor
Safety Considerations for Adjuvants including Update from HESI Meeting on Adjuvants and Autoimmunity—Ozzie Berger	Safety Considerations for Adjuvants including Update from HESI Meeting on Adjuvants and Autoimmunity—Ozzie Berger Excellent	Safety Considerations for Adjuvants including Update from HESI Meeting on Adjuvants and Autoimmunity—Ozzie Berger Good	Safety Considerations for Adjuvants including Update from HESI Meeting on Adjuvants and Autoimmunity—Ozzie Berger Average	Safety Considerations for Adjuvants including Update from HESI Meeting on Adjuvants and Autoimmunity—Ozzie Berger Fair	Safety Considerations for Adjuvants including Update from HESI Meeting on Adjuvants and Autoimmunity—Ozzie Berger Poor
Safety Considerations for Adjuvants including Update from HESI Meeting on Adjuvants and Autoimmunity—Sarah Gould	Safety Considerations for Adjuvants including Update from HESI Meeting on Adjuvants and Autoimmunity—Sarah Gould Excellent	Safety Considerations for Adjuvants including Update from HESI Meeting on Adjuvants and Autoimmunity—Sarah Gould Good	Safety Considerations for Adjuvants including Update from HESI Meeting on Adjuvants and Autoimmunity—Sarah Gould Average	Safety Considerations for Adjuvants including Update from HESI Meeting on Adjuvants and Autoimmunity—Sarah Gould Fair	Safety Considerations for Adjuvants including Update from HESI Meeting on Adjuvants and Autoimmunity—Sarah Gould Poor
Maternal Immunization and Nonclinical Safety Assessment—Martha Leibbrandt	Maternal Immunization and Nonclinical Safety Assessment—Martha Leibbrandt Excellent	Maternal Immunization and Nonclinical Safety Assessment—Martha Leibbrandt Good	Maternal Immunization and Nonclinical Safety Assessment—Martha Leibbrandt Average	Maternal Immunization and Nonclinical Safety Assessment—Martha Leibbrandt Fair	Maternal Immunization and Nonclinical Safety Assessment—Martha Leibbrandt Poor
Safety Assessment of Residuals and Contaminants in Vaccines—Deborah L. Novicki	Safety Assessment of Residuals and Contaminants in Vaccines—Deborah L. Novicki Excellent	Safety Assessment of Residuals and Contaminants in Vaccines—Deborah L. Novicki Good	Safety Assessment of Residuals and Contaminants in Vaccines—Deborah L. Novicki Average	Safety Assessment of Residuals and Contaminants in Vaccines—Deborah L. Novicki Fair	Safety Assessment of Residuals and Contaminants in Vaccines—Deborah L. Novicki Poor

Comments

Question Title

* 22. Symposium 17—Hot Topics

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
FDA Tobacco/eCig Initiatives—Michael Orr	FDA Tobacco/eCig Initiatives—Michael Orr Excellent	FDA Tobacco/eCig Initiatives—Michael Orr Good	FDA Tobacco/eCig Initiatives—Michael Orr Average	FDA Tobacco/eCig Initiatives—Michael Orr Fair	FDA Tobacco/eCig Initiatives—Michael Orr Poor
Update on Biosimiliars—Barbara J. Mounho-Zamora	Update on Biosimiliars—Barbara J. Mounho-Zamora Excellent	Update on Biosimiliars—Barbara J. Mounho-Zamora Good	Update on Biosimiliars—Barbara J. Mounho-Zamora Average	Update on Biosimiliars—Barbara J. Mounho-Zamora Fair	Update on Biosimiliars—Barbara J. Mounho-Zamora Poor
Animal Rights Extremists—John Sancenito	Animal Rights Extremists—John Sancenito Excellent	Animal Rights Extremists—John Sancenito Good	Animal Rights Extremists—John Sancenito Average	Animal Rights Extremists—John Sancenito Fair	Animal Rights Extremists—John Sancenito Poor
Update on FDA/CDER Guidances, Initiatives; ICH Activities—Timothy J. McGovern	Update on FDA/CDER Guidances, Initiatives; ICH Activities—Timothy J. McGovern Excellent	Update on FDA/CDER Guidances, Initiatives; ICH Activities—Timothy J. McGovern Good	Update on FDA/CDER Guidances, Initiatives; ICH Activities—Timothy J. McGovern Average	Update on FDA/CDER Guidances, Initiatives; ICH Activities—Timothy J. McGovern Fair	Update on FDA/CDER Guidances, Initiatives; ICH Activities—Timothy J. McGovern Poor
PETA Questions the Value of AAALAC Accreditation—What Is Going on Here?—David G. Serota	PETA Questions the Value of AAALAC Accreditation—What Is Going on Here?—David G. Serota Excellent	PETA Questions the Value of AAALAC Accreditation—What Is Going on Here?—David G. Serota Good	PETA Questions the Value of AAALAC Accreditation—What Is Going on Here?—David G. Serota Average	PETA Questions the Value of AAALAC Accreditation—What Is Going on Here?—David G. Serota Fair	PETA Questions the Value of AAALAC Accreditation—What Is Going on Here?—David G. Serota Poor
Update on Activities around the Ebola Outbreak—Beth Leffel	Update on Activities around the Ebola Outbreak—Beth Leffel Excellent	Update on Activities around the Ebola Outbreak—Beth Leffel Good	Update on Activities around the Ebola Outbreak—Beth Leffel Average	Update on Activities around the Ebola Outbreak—Beth Leffel Fair	Update on Activities around the Ebola Outbreak—Beth Leffel Poor
FDA Perspectives on Ebola Issues—Christopher Ellis	FDA Perspectives on Ebola Issues—Christopher Ellis Excellent	FDA Perspectives on Ebola Issues—Christopher Ellis Good	FDA Perspectives on Ebola Issues—Christopher Ellis Average	FDA Perspectives on Ebola Issues—Christopher Ellis Fair	FDA Perspectives on Ebola Issues—Christopher Ellis Poor

Comments

Question Title

* 23. What Topic(s) Would You Like to See included in Future Programs?

Question Title

* 24. Would You be Interested in Serving as a Symposium Moderator or Speaker?

Yes

Question Title

* 25. If YES, please complete the following:

Name:

Company:

Address:

Address 2:

City/Town:

State:

ZIP:

Country:

Email Address:

Phone Number:

Question Title

* 26. WELCOME RECEPTION - Please evaluate the quality of this special event

	Excellent	Good	Average	Fair	Poor
Entertainment	Entertainment Excellent	Entertainment Good	Entertainment Average	Entertainment Fair	Entertainment Poor
Food and Beverage	Food and Beverage Excellent	Food and Beverage Good	Food and Beverage Average	Food and Beverage Fair	Food and Beverage Poor
Location	Location Excellent	Location Good	Location Average	Location Fair	Location Poor
Seating	Seating Excellent	Seating Good	Seating Average	Seating Fair	Seating Poor
Networking	Networking Excellent	Networking Good	Networking Average	Networking Fair	Networking Poor

Comments

Question Title

* 27. AWARDS CEREMONY AND LUNCHEON - Please evaluate the quality of this special event

	Excellent	Good	Average	Fair	Poor
Speaker	Speaker Excellent	Speaker Good	Speaker Average	Speaker Fair	Speaker Poor
Food and Beverage	Food and Beverage Excellent	Food and Beverage Good	Food and Beverage Average	Food and Beverage Fair	Food and Beverage Poor
Seating	Seating Excellent	Seating Good	Seating Average	Seating Fair	Seating Poor
Audio-Visual	Audio-Visual Excellent	Audio-Visual Good	Audio-Visual Average	Audio-Visual Fair	Audio-Visual Poor
Acoustics	Acoustics Excellent	Acoustics Good	Acoustics Average	Acoustics Fair	Acoustics Poor
Networking	Networking Excellent	Networking Good	Networking Average	Networking Fair	Networking Poor

Comments

Question Title

* 28. POSTER RECEPTION - Please evaluate the quality of the poster session

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Food and Beverage	Food and Beverage Excellent	Food and Beverage Good	Food and Beverage Average	Food and Beverage Fair	Food and Beverage Poor
Networking	Networking Excellent	Networking Good	Networking Average	Networking Fair	Networking Poor

Comments

Question Title

* 29. TOXTROT - Please evaluate this new event

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Free T-Shirt	Free T-Shirt Excellent	Free T-Shirt Good	Free T-Shirt Average	Free T-Shirt Fair	Free T-Shirt Poor
Location	Location Excellent	Location Good	Location Average	Location Fair	Location Poor
Organization	Organization Excellent	Organization Good	Organization Average	Organization Fair	Organization Poor
Networking/Socializing	Networking/Socializing Excellent	Networking/Socializing Good	Networking/Socializing Average	Networking/Socializing Fair	Networking/Socializing Poor

Comments (please specify)

Question Title

* 30. TUESDAY BREAKFAST RECEPTION IN EXHIBIT HALL. New in 2014, in lieu of Tuesday Plenary Lecture.

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Food and Beverage	Food and Beverage Excellent	Food and Beverage Good	Food and Beverage Average	Food and Beverage Fair	Food and Beverage Poor
Networking	Networking Excellent	Networking Good	Networking Average	Networking Fair	Networking Poor

Comments (please specify)

Question Title

* 31. WINE TASTING (if applicable, for members only)— Please evaluate this new event

	Excellent	Good	Average	Fair	Poor
Overall	Overall Excellent	Overall Good	Overall Average	Overall Fair	Overall Poor
Location	Location Excellent	Location Good	Location Average	Location Fair	Location Poor
Networking	Networking Excellent	Networking Good	Networking Average	Networking Fair	Networking Poor
Member Benefit	Member Benefit Excellent	Member Benefit Good	Member Benefit Average	Member Benefit Fair	Member Benefit Poor

Comments (please specify)

Question Title

* 1. MEMBERSHIP STATUS

Question Title

* 2. AFFILIATION

Question Title

* 3. HOW DID YOU HEAR ABOUT THE MEETING?

Question Title

* 4. PLEASE EVALUATE THE OVERALL QUALITY OF THE SESSIONSMONDAY PLENARY LECTURE—Deborah Blum"The Poisoner's Guide to Life"

Question Title

* 5. Symposium 1—From Mice to Men, Development of Human Drugs and Biologics under the Animal Rule

Question Title

* 6. Symposium 2—What the AEL is the NOAEL?

Question Title

* 7. Symposium 3—Systems Toxicology: The Future of Risk Assessment

Question Title

* 8. Symposium 4—Anti-Drug Antibody-Independent Immune Responses to Biologics in Rodent Studies—Regulatory Success in Early Drug Development

Question Title

* 9. Symposium 5—Use of Humanized Mouse Models in DMPK and Safety Testing of Compounds

Question Title

* 10. Symposium 6—Targeted Cancer Therapeutics: Concepts and Strategies to Improve Oncology Drug Development

Question Title

* 11. Symposium 7—Breathe In, Breathe Out, It's Easy: What You Need to Know about Developing Inhaled Drugs

Question Title

* 12. Symposium 8—Cardiovascular Safety Evaluation—In Vitro to Humans

Question Title

* 13. Symposium 9—Centrally Administered Compounds in Small and Large Species—Dose Routes, Study Considerations, and Data Interpretation

Question Title

* 14. Symposium 10—Cytokines: The Good, the Bad, and the Deadly

Question Title

* 15. Symposium 11—Differentiating Adverse from Adaptive Changes in Toxicology

Question Title

* 16. Symposium 12—In Silico Methods for Mutagenicity Prediction vis a vis ICH M7 Guidance

Question Title

* 17. WEDNESDAY PLENARY LECTURE—Alison Van Eenennaam, PhD"Food and Feed Safety of Genetically Modified Organisms: The Hype and the Facts"

Question Title

* 18. Symposium 13—Novel Therapeutics in Oncology: Recent Advances and Considerations for Nonclinical Safety Evaluation

Question Title

* 19. Symposium 14—Applied Nanotoxicology

Question Title

* 20. Symposium 15—Stem Cells Research

Question Title

* 21. Symposium 16—Safety Assessment Updates for Preventive Vaccines and Vaccine Adjuvants

Question Title

* 22. Symposium 17—Hot Topics

Question Title

* 23. What Topic(s) Would You Like to See included in Future Programs?

Question Title

* 24. Would You be Interested in Serving as a Symposium Moderator or Speaker?

Question Title

* 25. If YES, please complete the following:

Question Title

* 26. WELCOME RECEPTION - Please evaluate the quality of this special event

Question Title

* 27. AWARDS CEREMONY AND LUNCHEON - Please evaluate the quality of this special event

Question Title

* 28. POSTER RECEPTION - Please evaluate the quality of the poster session

Question Title

* 29. TOXTROT - Please evaluate this new event

Question Title

* 30. TUESDAY BREAKFAST RECEPTION IN EXHIBIT HALL. New in 2014, in lieu of Tuesday Plenary Lecture.

Question Title

* 31. WINE TASTING (if applicable, for members only)— Please evaluate this new event

* 4. PLEASE EVALUATE THE OVERALL QUALITY OF THE SESSIONS

MONDAY PLENARY LECTURE—Deborah Blum

"The Poisoner's Guide to Life"

* 17. WEDNESDAY PLENARY LECTURE—Alison Van Eenennaam, PhD

"Food and Feed Safety of Genetically Modified Organisms: The Hype and the Facts"